Skip to main content
S&P 5007,722.72+0.73%DOW51,176.96+0.49%NASDAQ27,190.86+1.19%BTC$84,486.00-0.34%ETH$2,667.21-1.32%GOLD$4,172.10-0.72%OIL$91.26-1.73%
Smart Investors Daily
SID Premium
MR

NASDAQ · MRVI

Maravai LifeSciences Holdings, Inc.

Healthcare · Biotechnology

$7.50

Up+$0.40 (+5.33%)

Updated Oct 3, 2026, 12:05 AM

SID Score

6.1/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.03B
P/E ratio
-4.43
Dividend yield
0.00%
52-week range
$2.55 – $9.42
Volume
4.34M
Avg. volume
1.5M

Price performance · MRVI

MRVI price history

1M range · 19 trading sessions · Daily adjusted prices

Prices through Oct 1, 2026

MRVI closed at $7.50 after 19 trading sessions, up 2.46% for the selected period.

Last close
$7.50
Period change
+2.46%
Period low
$6.53
Period high
$7.66
Daily close
View OHLC price history
MRVI OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 1, 2026$7.67$7.73$7.325$7.504.34M
Sep 30, 2026$7.65$7.75$7.53$7.663.61M
Sep 29, 2026$7.52$7.70$7.435$7.651.76M
Sep 28, 2026$7.49$7.68$7.40$7.631.94M
Sep 25, 2026$7.61$7.65$7.245$7.601.93M
Sep 24, 2026$7.35$7.76$7.31$7.652.39M
Sep 23, 2026$7.42$7.48$7.13$7.371.55M
Sep 22, 2026$7.18$7.49$6.985$7.461.57M
Sep 21, 2026$7.00$7.235$6.92$7.172.3M
Sep 18, 2026$7.20$7.24$6.825$6.972.52M
Sep 17, 2026$6.98$7.515$6.98$7.273.45M
Sep 16, 2026$6.90$7.0892$6.78$6.843.08M
Sep 15, 2026$6.68$7.00$6.63$6.882.68M
Sep 14, 2026$6.53$6.81$6.53$6.6852.26M
Sep 11, 2026$6.84$6.91$6.485$6.533.26M
Sep 10, 2026$6.81$6.89$6.66$6.733.32M
Sep 9, 2026$7.08$7.16$6.925$6.952.21M
Sep 8, 2026$7.30$7.32$7.10$7.192.27M
Sep 4, 2026$7.25$7.435$7.17$7.321.55M

Latest MRVI news

The latest Smart Investors Daily articles mentioning MRVI.

Stock researchCompany · Overview

MRVI research

Overview

Company profile and research snapshot.

Company profile

Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$15.50
Implied upside
—
Analysts
—
MRVI recent ratings
DateFirmRatingTarget
Sep 9, 2026UBSNeutral—
Aug 7, 2026Wells FargoOverweight—
May 8, 2026Wells FargoOverweight—
Dec 15, 2025Wells FargoOverweight—
Aug 12, 2025RBC CapitalOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 29, 2026

TriLink BioTechnologies® Secures Additional China Patent for CleanCap® Technology, Adding Broad Composition-of-Matter Protection to Reinforce Its Global IP

SAN DIEGO, September 29, 2026--TriLink BioTechnologies, LLC (TriLink®), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, today announced it has been granted a new patent from the China National Intellectual Property Administration (CNIPA), Patent number ZL202511246658.5., named "Compositions and Methods for Synthesizing 5'-Capped RNAs." The patent marks TriLink's second granted CleanCap® patent in China within a matter of months, and expand

Yahoo · Sep 25, 2026

Is Maravai LifeSciences Holdings (MRVI) Cheap If Cash Flow Recovers?

Maravai LifeSciences Holdings has seen its share price swing sharply in recent years, which raises a straightforward question for anyone looking at the stock today. Is the current US$7.65 price supported by the cash flows the business can generate over time, based on a Discounted Cash Flow (DCF) view of its intrinsic value? The stock has delivered a 171.3% return over the past year, which puts real pressure on the question of whether that move is fully backed by the cash the business is...

Yahoo · Sep 24, 2026

Maravai LifeSciences Holdings (MRVI) Rebounded Sharply, Is The Upside Already Priced In?

Maravai LifeSciences Holdings (MRVI) has been drawing attention after recent share price swings, with the stock closing at US$7.37 on 24 September 2026. Investors are weighing mixed return patterns across different holding periods. Recent trading in Maravai LifeSciences Holdings has been choppy, with a 7-day share price return of 7.75% but a 30-day move that is down 12.57%, while the 90-day gain of 20.42% and year to date share price return of 116.76% signal momentum that has cooled recently...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By